ClinicalTrials.gg
CompletedNCT07186946Updated Jan 14, 2026

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

A Phase 1 interventional study of THRV-1268 and Placebo in Heart Failure, sponsored by Thryv Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Thryv Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,277th of 1,601
16 · median 65
Started
2025
with 107 others
Phase 1
118 of 2,157
18 open now
Registered
2,056th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,277th largest by enrollment of the 1,601 interventional ones that give a count, is one of 108 that started in 2025, is one of 118 in phase 1, and was the 2,056th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

A research study that involves the use of an investigational drug called THRV-1268. The main purpose is to measure the safety (whether it causes any side effects) and tolerability (if it does cause any side effects, how well your body is able to handle them) in healthy obese adults. This study will also look at how the drug moves through the body, is absorbed, distributed, metabolized and eliminated.

03

Conditions studied

  • Heart Failure

Keywords

  • heart failure
  • obesity
  • cardiometabolic
  • atrial fibrillation
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated Document (ICD).
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Healthy adult male or female participants.
  • If female, meets one of the following criteria:

    1. Women of (WOCBP) who agrees to use any of the acceptable methods:

      1. Abstinence from heterosexual intercourse from Screening through at least 30 days from last study dose.
      2. One of the following highly-effective contraception methods:

        1. intrauterine device (with or without hormones) used from at least 28 days prior to Screening through to at least 30 days from last study dose
        2. male partner vasectomized at least 6 months prior to Screening visit
      3. Double-barrier contraception method (e.g., condom and spermicide) used from 28 days prior to Screening through at least 30 days from last study dose Or
    2. Physiological status, defined as the absence of menses for at least 12 months following cessation of all exogenous hormonal treatments (without an alternative medical condition) at Screening and prior to the first study drug administration.

      Or

    3. Surgically sterile, defined as those who have had hysterectomy, bilateral oophorectomy and/or bilateral salpingectomy, or bilateral tubal ligation/occlusion.
  • Male volunteers agree to use a double-barrier method (e.g., condom and spermicide) or agree to remain abstinent from heterosexual intercourse at the time of Screening, during the study, and for 90 days following the study dose. Men who are biologically capable of fathering children must also agree to refrain from sperm donation for the duration of the treatment period and for at least 90 days after the last study dose.
  • Aged at least 18 years but not older than 55 years (both years inclusive) at screening.
  • (BMI) more than or equal to 30.0 kg/m2 and up to 40.0 kg/m2 (both inclusive).
  • Body weight ≥ 90.0 kg.
  • Non- or ex-smoker (An ex-smoker is defined as someone who completely stopped using nicotine products for at least 90 days prior to the first study drug administration).
  • Have no diseases captured in the medical history or evidence of clinically significant findings in the physical examination (including vital signs), safety clinical laboratory tests, and/or , as determined by an Investigator.
  • Ability to swallow whole tablets.

Exclusion criteria

Exclusion and Restriction Criteria

  • cardiovascular, gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, or psychiatric disease, or any other condition, which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study results.
  • Female who is lactating.
  • Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration or planning to be pregnant.
  • Male participants with a history of oligospermia or azoospermia or any other disorder of the reproductive system.
  • Male participants who are undergoing treatment or evaluation for infertility.
  • The average of 3 BP measurements performed after resting supine quietly for at least 5 min, and approximately 1 min between each measurement:
  • Screening or baseline (Day -1, Period 1) :

    1. systolic BP \<100 mmHg or >145 mmHg;
    2. diastolic BP \<50 mmHg or >95; or
    3. pulse rate ≤ 50 beats per minute (bpm) using a validated digital BP device.
  • These can be repeated in triplicate once after an additional quiet resting period.
  • Orthostatic BP performed after at least 5 mins in supine position and then after standing for at least 2 minutes but no more than 3 minutes with a reduction in systolic BP >20 mmHg, or a reduction in diastolic BP >10 mmHg, using a validated digital BP device.
  • History of significant to THRV-1268, kinase inhibitors or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
  • Screening and check-in at Period 1: 12-lead demonstrating at least one of the following:

    1. Heart rate ≤50 bpm or >100 bpm.
    2. PR interval >200 ms;
    3. QRS duration >110 ms, or
    4. ≥ 450 ms in males and 470 ms in females;
    5. atrioventricular block; branch bundle block, significant ST T wave abnormalities or flat T waves that could interfere with QT analysis
  • History or evidence of any of the following: myocardial infarction; cardiac valvulopathy; cardiac surgery revascularization (coronary artery bypass grafting or percutaneous, transluminal coronary angioplasty); unstable angina; cerebrovascular accident, stroke, or ; pacemaker; AF, flutter, or nonsustained or sustained ventricular tachycardia; orthostatic hypotension or orthostatic dizziness or lightheadedness, pulmonary arterial hypertension; sick sinus syndrome, second- or third-degree atrioventricular block; uncontrolled hypertension; congestive heart failure; personal or family history of sudden death or long QT syndrome; unexplained syncope or syncope within the last 3 years regardless of etiology.
  • Immunization with a Coronavirus Disease (COVID-19) vaccine in the 14 days prior to the first study drug administration.
  • Scheduled immunization with a COVID-19 vaccine during the study that, in the opinion of an Investigator, could potentially interfere with participant participation, participant safety, study results, or any other reason.
  • Use of in the 28 days or 5 half-lives (whichever is longer) prior to the first study drug administration.
  • Major surgery with prolonged immobilization in the 28 days prior to the first study drug administration.
  • Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic).
  • Any clinically significant illness in the 28 days prior to the first study drug administration.
  • Use of any over-the-counter or nutritional supplements in the last 7 days prior to the first study drug administration and during the study, that in the opinion of an Investigator would put into question the status of the participant as healthy.
  • Use of any prescription drugs (including hormonal or hormone replacement therapy) in the 28 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the participant as healthy.
  • Use of St. John's Wort in the 28 days prior to the first study drug administration.
  • Any history of tuberculosis.
  • value below the lower limit of the reference laboratory at Screening, unless deemed non-significant by the Investigator.
  • Abnormal screening values in potassium, magnesium, (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, alkaline phosphatase, total , and direct bilirubin values, unless deemed non-significant by the Investigator
  • Positive test result for urine alcohol and/or drugs of abuse at Screening or prior to the first drug administration.
  • Current or history of alcohol or substance abuse, with the exception of being fully recovered with no use of alcohol or substances of abuse within the 12 months prior to Screening
  • Positive screening results to Ag/Ab combo, surface antigen or virus antibody tests.
  • Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
  • History of prior administration of THRV-1268 or inclusion in a previous cohort for this clinical study.
  • Treatment with any product within 30 days or five half-lives of the drug (whichever is longer) prior to Screening.
  • Unable or unwilling to adhere to the lifestyle and dietary requirements described in Section 5.5.
  • Special diet or substantial changes in eating habits 1 month prior to Screening.
  • Donation of 500 mL or more of blood (blood services, clinical studies, etc.) in the 56 days prior to Screening or donation of plasma within 7 days prior to Screening.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (SAD) THRV-1268 low dose (100mg)

    In Period 1 of cohort 1 will receive a single oral dose of THRV-1268 100mg

    Drug: THRV-1268 · Drug: Placebo

  • Experimental
    THRVY-1268 high dose (200mg)

    In cohort 2, will receive a single oral dose of THRV-1268 200mg

    Drug: THRV-1268 · Drug: Placebo

Interventions

  • THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Evalute the safety and tolerability of a single oral dose

    -Occurance of treatment emergent adverse events

    Time frame: 7 days

Secondary outcomes

  1. Pharmacokinetic THRV-1268 Tmax

    Time to maximum observed plasma drug concentration

    Time frame: From 0 to 24 hours

  2. Pharmacokinetic THRV-1268 t1/2

    half-life

    Time frame: From 0 to 24 hours

  3. Pharmacokinetic THRV-1268 Cmax

    Maximum observed plasma drug concentration

    Time frame: From 0 to 24 hours

  4. Pharmacokinetic THRV-1268 AUC0-t

    Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration

    Time frame: From 0 to 24 hours

  5. Evaluate and compare the bioavailability

    To evaluate the relative bioavailability (Area under the plasma concentration versus time curve (AUC)) of THRV-1268 tablet relative to THRV-1268 API powder for oral

    Time frame: From 0 to 24 hours

07

Study locations

1 site
  • Dr. Vince Clinical Research
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Oct 2025, 1 month.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 22, 2025
StartActual
Sep 15, 2025
Primary completionActual
Oct 20, 2025
CompletionActual
Oct 20, 2025
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07186946
Lead sponsor
Thryv Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Sep 15, 2025
Primary completion
Oct 20, 2025
Completion
Oct 20, 2025
Last update
Jan 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THRV-1268

Start the discussion